BIOLASE, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Concentrations

Concentrations

9 Months Ended

Sep. 30, 2015

Risks And Uncertainties [Abstract]

Concentrations

NOTE 11—CONCENTRATIONS

Revenue from the Company’s products for the three and nine months ended September 30, 2015 and 2014 are as follows:

	Three Months Ended						Nine Months Ended
	September 30						September 30
	2015			2014			2015			2014
Laser systems		65.3	%		57.9	%		65.2	%		60.2	%
Imaging systems		6.4	%		11.0	%		4.7	%		9.5	%
Consumables and other		13.1	%		12.6	%		15.5	%		13.6	%
Services		14.9	%		18.2	%		14.1	%		16.3	%
License fees and royalties		0.3	%		0.3	%		0.5	%		0.4	%
Total revenue		100.0	%		100.0	%		100.0	%		100.0	%

No individual customer represented more than 10% of the Company’s revenue for the three and nine months ended September 30, 2015 or 2014.

The Company maintains its cash and cash equivalent accounts with established commercial banks. Such cash deposits periodically exceed the Federal Deposit Insurance Corporation insured limit.

As of September 30, 2015, one customer represented 11.4% of the Company’s accounts receivable. Amounts due are expected to be collected in full by the Company. No individual customer represented more than 10% of the Company’s accounts receivable at December 31, 2014.

The Company currently purchases certain key components of its products from single suppliers. Although there are a limited number of manufacturers of these key components, management believes that other suppliers could provide similar key components on comparable terms. A change in suppliers, however, could cause delays in manufacturing and a possible loss of sales, which could adversely affect the Company’s business, results of operations, and financial condition.